156 related articles for article (PubMed ID: 38048851)
21. Disposition of CP-671, 305, a selective phosphodiesterase 4 inhibitor in preclinical species.
Kalgutkar AS; Choo E; Taylor TJ; Marfat A
Xenobiotica; 2004 Aug; 34(8):755-70. PubMed ID: 15690763
[TBL] [Abstract][Full Text] [Related]
22. Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human.
Salphati L; Pang J; Plise EG; Lee LB; Olivero AG; Prior WW; Sampath D; Wong S; Zhang X
Drug Metab Dispos; 2012 Sep; 40(9):1785-96. PubMed ID: 22696419
[TBL] [Abstract][Full Text] [Related]
23. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and metabolism of AMG 232, a novel orally bioavailable inhibitor of the MDM2-p53 interaction, in rats, dogs and monkeys: in vitro-in vivo correlation.
Ye Q; Jiang M; Huang WT; Ling Y; Olson SH; Sun D; Xu G; Yan X; Wong BK; Jin L
Xenobiotica; 2015; 45(8):681-92. PubMed ID: 25798742
[TBL] [Abstract][Full Text] [Related]
25. Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs.
Beconi MG; Reed JR; Teffera Y; Xia YQ; Kochansky CJ; Liu DQ; Xu S; Elmore CS; Ciccotto S; Hora DF; Stearns RA; Vincent SH
Drug Metab Dispos; 2007 Apr; 35(4):525-32. PubMed ID: 17220241
[TBL] [Abstract][Full Text] [Related]
26. Disposition and metabolism of the G protein-coupled receptor 40 agonist TAK-875 (fasiglifam) in rats, dogs, and humans.
Kogame A; Lee R; Pan L; Sudo M; Nonaka M; Moriya Y; Higuchi T; Tagawa Y
Xenobiotica; 2019 Apr; 49(4):433-445. PubMed ID: 29557709
[TBL] [Abstract][Full Text] [Related]
27. Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2.
Marathe P; Tang Y; Sleczka B; Rodrigues D; Gavai A; Wong T; Christopher L; Zhang H
J Pharm Sci; 2010 Aug; 99(8):3579-93. PubMed ID: 20166197
[TBL] [Abstract][Full Text] [Related]
28. In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species.
Venkatesh PR; Goh E; Zeng P; New LS; Xin L; Pasha MK; Sangthongpitag K; Yeo P; Kantharaj E
Biol Pharm Bull; 2007 May; 30(5):1021-4. PubMed ID: 17473456
[TBL] [Abstract][Full Text] [Related]
29. In vitro and in vivo metabolism and pharmacokinetics of BMS-562086, a potent and orally bioavailable corticotropin-releasing factor-1 receptor antagonist.
Zhou L; Dockens RC; Liu-Kreyche P; Grossman SJ; Iyer RA
Drug Metab Dispos; 2012 Jun; 40(6):1093-103. PubMed ID: 22381334
[TBL] [Abstract][Full Text] [Related]
30. Metabolism and disposition in rats, dogs, and humans of erdafitinib, an orally administered potent pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor.
Scheers E; Borgmans C; Keung C; Bohets H; Wynant I; Poggesi I; Cuyckens F; Leclercq L; Mamidi RNVS
Xenobiotica; 2021 Feb; 51(2):177-193. PubMed ID: 32902324
[TBL] [Abstract][Full Text] [Related]
31. Clinical pharmacology of axitinib.
Chen Y; Tortorici MA; Garrett M; Hee B; Klamerus KJ; Pithavala YK
Clin Pharmacokinet; 2013 Sep; 52(9):713-25. PubMed ID: 23677771
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics and ADME Characterization of Intravenous and Oral [
Zamek-Gliszczynski MJ; Kenworthy D; Bershas DA; Sanghvi M; Pereira AI; Mudunuru J; Crossman L; Pirhalla JL; Thorpe KM; Dennison JMTJ; McLaughlin MM; Allinder M; Swift B; O'Connor-Semmes RL; Young GC
Drug Metab Dispos; 2021 Dec; 49(12):1109-1117. PubMed ID: 34625435
[TBL] [Abstract][Full Text] [Related]
33. Metabolism, excretion, and pharmacokinetics of ((3,3-difluoropyrrolidin-1-yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone, a dipeptidyl peptidase inhibitor, in rat, dog and human.
Sharma R; Sun H; Piotrowski DW; Ryder TF; Doran SD; Dai H; Prakash C
Drug Metab Dispos; 2012 Nov; 40(11):2143-61. PubMed ID: 22896728
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH
Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512
[TBL] [Abstract][Full Text] [Related]
35. Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERα covalent antagonist (SERCA).
Rioux N; Smith S; Korpal M; O'Shea M; Prajapati S; Zheng GZ; Warmuth M; Smith PG
Cancer Chemother Pharmacol; 2019 Jan; 83(1):151-160. PubMed ID: 30386887
[TBL] [Abstract][Full Text] [Related]
36. Absorption, Distribution, Metabolism, and Excretion of [
James AD; Kulmatycki K; Poller B; Romeo AA; Van Lier JJ; Klein K; Pearson D
Drug Metab Dispos; 2023 Jul; 51(7):873-883. PubMed ID: 37308298
[TBL] [Abstract][Full Text] [Related]
37. Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor.
Pasha MK; Jayaraman R; Reddy VP; Yeo P; Goh E; Williams A; Goh KC; Kantharaj E
Drug Metab Lett; 2012 Mar; 6(1):33-42. PubMed ID: 22372550
[TBL] [Abstract][Full Text] [Related]
38. Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. In vitro studies and correlation with in vivo data.
Walker DK; Alabaster CT; Congrave GS; Hargreaves MB; Hyland R; Jones BC; Reed LJ; Smith DA
Drug Metab Dispos; 1996 Apr; 24(4):447-55. PubMed ID: 8801060
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics and mass balance of vericiguat in rats and dogs and distribution in rats.
Janssen W; Schwarz T; Bütehorn U; Steinke W; Sandmann S; Lang D; Kern A; Hucke F; Gerisch M
Xenobiotica; 2022 May; 52(5):453-462. PubMed ID: 35616579
[TBL] [Abstract][Full Text] [Related]
40. In Vitro ADME and Preclinical Pharmacokinetics of Ulotaront, a TAAR1/5-HT
Xiao G; Chen YL; Dedic N; Xie L; Koblan KS; Galluppi GR
Pharm Res; 2022 May; 39(5):837-850. PubMed ID: 35484370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
